CLINICAL_TRIALS
ClinicalTrials.gov record update
Expanded Access Program (EAP) to Provide Epcoritamab (GEN3013) to Eligible Patients With Relapsed or Refractory Large B-cell Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05733650
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:09.162947+00:00
- Published At
- 2023-05-25T00:00:00+00:00
- Record Updated At
- 2023-05-25
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Large B-cell Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "High Grade B-cell Lymphoma (HGBCL)", "Grade 3B Follicular Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-05-25"- protocolSection.identificationModule.nctId
"NCT05733650"- protocolSection.identificationModule.officialTitle
"Expanded Access Program (EAP) to Provide Epcoritamab (GEN3013) to Eligible Patients With Relapsed or Refractory Large B-cell Lymphoma"- protocolSection.statusModule.overallStatus
"APPROVED_FOR_MARKETING"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.